Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes

被引:20
作者
Laugier-Robiolle, Stephanie [1 ,2 ]
Verges, Bruno [3 ]
Le Bras, Maelle [4 ]
Gand, Elise [1 ,2 ]
Bouillet, Benjamin [3 ]
Saulnier, Pierre-Jean [5 ]
Le May, Cedric [6 ]
Pichelin, Matthieu [7 ]
Marechaud, Richard [1 ,2 ]
Petit, Jean-Michel [3 ]
Hadjadj, Samy [1 ,2 ,5 ,8 ]
Cariou, Bertrand [7 ]
机构
[1] CHU Poitiers, Endocrinol Diabetol, Poitiers, France
[2] CHU Poitiers, CIC1402, Poitiers, France
[3] Univ Bourgogne, Dept Endocrinol, INSERM, CRI 866,CHU Dijon, Dijon, France
[4] CHU Nantes, Inst Thorax, Dept Endocrinol, Nantes, France
[5] INSERM, CIC1402, Poitiers, France
[6] Univ Nantes, Inst Thorax, INSERM, CNRS, Nantes, France
[7] Univ Nantes, CHU Nantes, Dept Endocrinol, Inst Thorax,INSERM,CNRS, Nantes, France
[8] Univ Poitiers, UFR Med Pharm, Poitiers, France
关键词
dyslipidaemia; lipid-lowering therapy; type; 1; diabetes; SUBTILISIN/KEXIN TYPE 9; CARDIOVASCULAR-DISEASE; ASSOCIATION; EXPRESSION; INSULIN;
D O I
10.1111/dom.12819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of LDL cholesterol metabolism. Little is known, however, about the regulation of PCSK9 in patients with type 1 diabetes (T1D). In the present study, we aimed to determine the relationship between circulating PCSK9 and metabolic variables in T1D. Plasma PCSK9 levels were measured in 195 people with T1D (mean age 38.8 years, mean diabetes duration 17.2 years, mean glycated haemoglobin [HbA1c] 8.3%), who were free of any lipid-lowering agent. Plasma PCSK9 was positively correlated with LDL cholesterol (P =.0007), triglycerides (P =.004), apolipoprotein B (P =.005), HbA1c (P =.003), systolic (P =.003) and diastolic (P =.001) blood pressure and body mass index (0.02). In multivariate analysis, PCSK9 concentration was independently associated with HbA1c (P =.02) and LDL cholesterol (P =.03). After classifying patients according to HbA1c tertile, the correlation between PCSK9 and LDL cholesterol was only observed in the highest tertile (P =.0006; Rho = 0.43), whereas no correlation was found in the lowest and intermediate tertiles. This study suggests that good glycaemic control abolishes the positive relationship between PCSK9 and LDL cholesterol in patients with T1D; however, the underlying molecular mechanisms remain to be established.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 50 条
  • [41] Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
    Maadjhou, Camille
    Mbacham, Wilfred
    Sobngwi, Eugene
    Mbanya, Jean Claude
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2791 - 2797
  • [42] Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes
    Didas, Nutsiwat
    Thitisopee, Witsawat
    Porntadavity, Sureerut
    Jeenduang, Nutjaree
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (09) : 1725 - 1732
  • [43] Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes
    Emory, Hamlin
    Mizrahi, Neptune
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2017, 14 (02) : 163 - 165
  • [44] Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes
    Ghouse, Jonas
    Isaksen, Jonas L.
    Skov, Morten W.
    Lind, Bent
    Svendsen, Jesper H.
    Kanters, Jorgen K.
    Olesen, Morten S.
    Holst, Anders G.
    Nielsen, Jonas B.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (02) : 231 - 242
  • [45] Relationship between glycaemic control and lipid profile in type 2 diabetes mellitus patients in a low-resource setting
    Nnakenyi, Ifeyinwa Dorothy
    Nnakenyi, Emeka Francis
    Parker, Elijah Joshua
    Uchendu, Nene Orizu
    Anaduaka, Emeka Godwin
    Ezeanyika, Lawrence Uchenna
    [J]. PAN AFRICAN MEDICAL JOURNAL, 2022, 41
  • [46] Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients
    Cariou, Bertrand
    Le Bras, Maelle
    Langhi, Cedric
    Le May, Cedric
    Guyomarc'h-Delasalle, Beatrice
    Krempf, Michel
    Costet, Philippe
    [J]. ATHEROSCLEROSIS, 2010, 211 (02) : 700 - 702
  • [47] Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells
    Ali, Amjad
    Unnikannan, Hema
    Shafarin, Jasmin
    Bajbouj, Khuloud
    Taneera, Jalal
    Muhammad, Jibran Sualeh
    Hasan, Haydar
    Salehi, Albert
    Awadallah, Samir
    Hamad, Mawieh
    [J]. ENDOCRINE, 2022, 76 (03) : 543 - 557
  • [48] Relationship between liver and cardiometabolic health in type 1 diabetes
    Tas, Emir
    Vu, Bach-Mai Katherine
    Mendizabal, Brenda
    Libman, Ingrid
    Muzumdar, Radhika
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [49] Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes
    Bao, Yu-Qian
    Zhou, Mi
    Zhou, Jian
    Lu, Wei
    Gao, Yun-Chao
    Pan, Xiao-Ping
    Tang, Jun-Ling
    Lu, Hui-Juan
    Jia, Wei-Ping
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2011, 38 (01): : 50 - 54
  • [50] Food Behaviour and Metabolic Characteristics of Children and Adolescents with Type 1 Diabetes: Relationship to Glycaemic Control
    Catamo, Eulalia
    Tornese, Gianluca
    Dovc, Klemen
    Tinti, Davide
    Di Tonno, Raffaella
    Cauvin, Vittoria
    Barbi, Egidio
    Franceschi, Roberto
    Bonfanti, Riccardo
    Rabbone, Ivana
    Battelino, Tadej
    Robino, Antonietta
    [J]. FOODS, 2024, 13 (04)